Stockscreener 앱 받기
1.52
2.70%
0.04
시장 영업 전:
1.63
0.11
+7.24%
전일 마감가:
$1.48
열려 있는:
$1.52
하루 거래량:
1.12M
Relative Volume:
0.79
시가총액:
$109.90M
수익:
-
순이익/손실:
$-61.80M
주가수익비율:
-1.0002
EPS:
-1.5197
순현금흐름:
$-70.37M
1주 성능:
-0.65%
1개월 성능:
-1.30%
6개월 성능:
+13.43%
1년 성능:
-24.00%
1일 변동 폭
$1.46
$1.56
1주일 범위
$1.28
$1.56
52주 변동 폭
$0.8719
$3.08
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.52 | 109.90M | 0 | -61.80M | -70.37M | -1.5197 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-08-28 | 개시 | Jefferies | Buy |
| 2025-06-03 | 재개 | Piper Sandler | Overweight |
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
Biomea Fusion to present new icovamenib data at American Diabetes Association event - Traders Union
Biomea Fusion Announces Late-Breaking Poster Presentations on Icovamenib at ADA 86th Scientific Sessions - Quiver Quantitative
Three diabetes studies put Biomea's icovamenib in ADA late-breakers - Stock Titan
Biomea Fusion Announces Poster Presentations of Icovamenib - GlobeNewswire
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions - GlobeNewswire Inc.
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026 - Yahoo Finance
Citizens initiates Biomea Fusion stock coverage citing diabetes treatment potential - Investing.com
Biomea Fusion Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
BMEA Forecast, Price Target & Analyst Ratings | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib - MarketBeat
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 DiabetesSlideshow (NASDAQ:BMEA) 2026-04-28 - Seeking Alpha
Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital - MarketBeat
Biomea Fusion Reports Positive Phase 2 T1D Trial Results - TipRanks
Biomea Fusion | 8-K: Current report - Moomoo
Phase 2 icovamenib T1D data from Biomea Fusion (NASDAQ: BMEA) show 52% C-peptide gain - Stock Titan
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment - markets.businessinsider.com
Biomea reports positive type 1 diabetes trial results By Investing.com - Investing.com South Africa
Biomea reports positive type 1 diabetes trial results - Investing.com UK
Biomea Fusion reports 52 percent C peptide AUC gain in Phase 2 diabetes trial at week 12 - Traders Union
Biomea Fusion | DEF 14A: Definitive information statements - Moomoo
Biomea Fusion Reports Promising 52-Week Results for Icovamenib in Phase 2 Trial for Type 1 Diabetes - Quiver Quantitative
In a small T1D trial, 12 weeks of treatment preserved C-peptide for 52 weeks - Stock Titan
Biomea Fusion (NASDAQ: BMEA) sets 2026 virtual meeting, director votes and Deloitte audit - Stock Titan
[ARS] Biomea Fusion, Inc. SEC Filing - Stock Titan
Biomea Fusion, Inc. Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment - marketscreener.com
Biomea Fusion to Attend H.C. Wainwright Global Investment Conference - Sangri Today
Biomea Fusion announces pricing of public offering of securities - MSN
Biomea (BMEA) Stock Prediction: What’s Next After Recent Move | Q4 2025: Profit SurprisesRating Downgrade - Cổng thông tin điện tử Tỉnh Sơn La
Biomea Fusion, Inc. Common Stock (BMEA) Stock Price Today & Analysis - Gotrade
BMEA Technical Analysis | Trend, Signals & Chart Patterns | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
BMEA Should I Buy - Intellectia AI
BMEA.O PE Ratio & Valuation, Is BMEA.O Overvalued - Intellectia AI
BMEA.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BMEA.O Technical Analysis & Stock Price Forecast - Intellectia AI
BMEA News & Events - Intellectia AI
BMEA.O Forecast — Price Prediction for 2026. Should I Buy BMEA.O? - Intellectia AI
Biomea (BMEA) Stock Index Trade (Smart Money Flows) 2026-04-15Trader Community Insights - Xã Thanh Hà
COVALENT-212 study enrolls participants for icovamenib diabetes research, Biomea Fusion initiates - Traders Union
Biomea Fusion warns diabetes remains poorly controlled despite standard therapies - Traders Union
Biomea Fusion Advances Phase 2 Add-On Therapy Trial in Ozempic-Treated Diabetes - TipRanks
BMEA: Analyst Rating Maintained at Buy with Price Target Unchang - GuruFocus
Is Biomea (BMEA) Stock Breaking Resistance | BMEA Q4 Earnings: Beats Estimates by $0.53Community Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion (BMEA) awards 452,512 stock options to director and officer Erdtmann - Stock Titan
Biomea Fusion (BMEA) interim CEO awarded 667,477 options at $1.49 strike - Stock Titan
Icovamenib development timeline includes Phase II updates and 52-week data in 2026 - Traders Union
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies - Investing News Network
BMEA Technical Analysis & Stock Price Forecast - Intellectia AI
Biomea Fusion Announces Initiation of Phase II Trials COVALENT-211 and COVALENT-212 for Icovamenib in Type 2 Diabetes Patients - Quiver Quantitative
Biomea Fusion Announces First Patient Dosed in Newly - GlobeNewswire
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):